Professor Banerji's group focuses on the development and validation of quantifiable and reproducible robust pharmacodynamic biomarkers in normal and tumour tissue that can be used in first-in-human studies.
Professor Udai Banerji champions multidisciplinary working at the interface between early phase clinical trials, drug discovery and translational research related to drug resistance. He is Deputy Director of the Drug Development Unit at The ICR and Royal Marsden, and as a key member of the Centre for Cancer Drug Discovery, also heads the Clinical Pharmacodynamics Biomarker Group and the Clinical Pharmacology-Adaptive Therapy Group.